Shareholders that lost money on Actinium Pharmaceuticals, Inc. (ATNM) should contact Levi & Korsinsky about Securities Fraud Investigation - ATNMAccesswire • 08/09/24
Shareholder Rights Advocates at Levi & Korsinsky Investigate Actinium Pharmaceuticals, Inc. (ATNM) Regarding Possible Securities Fraud ViolationsAccesswire • 08/08/24
ATNM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Actinium Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm!Accesswire • 08/08/24
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmPRNewsWire • 08/08/24
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ATNMAccesswire • 08/08/24
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia TreatmentBenzinga • 08/05/24
Actinium Pharma's stock craters after FDA says Phase 3 trial of leukemia treatment not enough for BLAMarket Watch • 08/05/24
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.PRNewsWire • 08/05/24
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant IndicationsPRNewsWire • 08/01/24
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia UniversityPRNewsWire • 07/25/24
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit USPRNewsWire • 07/25/24
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 ProductionBusiness Wire • 07/22/24
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 06/20/24
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA CongressPRNewsWire • 06/17/24
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA TrialPRNewsWire • 06/14/24
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingPRNewsWire • 06/11/24
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingPRNewsWire • 06/10/24
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market OpportunityPRNewsWire • 05/15/24
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the PhaPRNewsWire • 05/14/24
